Federal Trade Commission accused Ovation Pharma of price-gouging on Ondocin and NeoProfen

The two drugs are used to treat premature infants born with a common heart defect called ductus arteriosus.  According to Reuters, Ovation bought the rights to Indocin in 2005 and to NeoProfen in 2006.  After consolidating and eliminating the potential competition between the two medications, Ovation immediately raised the price by about 1300 percent, from $36 dollars to $1300 dollars per vial.  About 3,000 children born in the U.S. each year require treatment with the drug.